O-304
目录号 : GC19269
A pan-activator of AMPK
Cas No.:1261289-04-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
O-304 is a small molecule AMPK activator.
O-304 efficiently increases glucose uptake and reduces insulin resistance in skeletal muscle a primary cause of obesity-induced T2D. O-304 also reverses β-cell stress/dysfunction and induce β-cell rest. O-304 also increases energy expenditure and protects against diet induced obesity, fatty liver, hyperlipidemia and diabetes. CVD remains a major cause of death of T2 diabetics, and O-304 increases peripheral blood flow and left ventricular function, and acts as an "Exercise mimetic". Thus, as an AMPK activator O-304 uniquely mitigates many of the metabolic and cardiovascular complications associated with the obesity epidemic. O-304 has the unique potential to increase glucose uptake and reduce insulin resistance in newly diagnosed T2 diabetics and as such prevent the associated β-cell hyperactivity/failure and progression of the disease[1].
References:
[1]. Periodic Reporting for period 1-AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes).
| Cas No. | 1261289-04-6 | SDF | |
| Canonical SMILES | O=C(NC(SN1CC2=CC=C(Cl)C=C2)=NC1=O)C3=CC=C(Cl)C=C3 | ||
| 分子式 | C16H11Cl2N3O2S | 分子量 | 380.25 |
| 溶解度 | DMSO : 30 mg/mL (78.90 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6298 mL | 13.1492 mL | 26.2985 mL |
| 5 mM | 0.526 mL | 2.6298 mL | 5.2597 mL |
| 10 mM | 0.263 mL | 1.3149 mL | 2.6298 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。